Overall, these studies demonstrated a remarkable role of DOT1L in AML cells irrespective of MLL fusion proteins, and based on these preclinical results, further investigation of combination treatments employing DOT1L inhibitors is warranted. This evidence concerns the gene KMT2A and acute myeloid leukemia.